Entero Therapeutics, Inc. (ENTO NASDAQ) stock market data APIs
$0.3903
0.01(2.6%)
as of July 1, 2025
Try our APIs with
free plan!
Entero Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Prev. Close
0.3903
Open
0.3999
High
0.407
Low
0.3886
52 wk Range
0.185-1.27
Market Cap
1 906 K
Shares Outstanding
4 766 K
EPS
-0.2814
Beta
0.84
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Entero Therapeutics, Inc. data using free add-ons & libraries
Get Entero Therapeutics, Inc. Fundamental Data
Entero Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -7 337 699
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Entero Therapeutics, Inc. News
New
Entero Therapeutics receives Nasdaq extension to regain equity compliance
Entero Therapeutics, Inc. (NASDAQ:ENTO) announced Monday that it has received an extension from the Nasdaq Stock Market to regain compliance with the minimum stockholders’ equity requirement for con...
Entero Therapeutics Appoints Richard Paolone as CEO
BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the devel...
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members
BOCA RATON, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the devel...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
